Avanos Medical (NYSE:AVNS) Rating Increased to Buy at Wall Street Zen

Avanos Medical (NYSE:AVNS) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Other research analysts have also recently issued reports about the company. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Avanos Medical currently has a consensus rating of “Reduce”.

Avanos Medical Stock Down 2.5%

NYSE AVNS opened at $13.51 on Friday. The firm has a market cap of $628.30 million, a PE ratio of -8.55 and a beta of 1.07. Avanos Medical has a one year low of $9.30 and a one year high of $15.68. The stock’s 50 day simple moving average is $13.82 and its 200 day simple moving average is $12.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.15 and a quick ratio of 1.26.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. The firm had revenue of $180.90 million during the quarter, compared to analysts’ expectations of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The business’s revenue was up .7% on a year-over-year basis. During the same period last year, the firm posted $0.43 EPS. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. As a group, sell-side analysts forecast that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avanos Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC bought a new position in Avanos Medical in the fourth quarter valued at about $234,000. Alpine Global Management LLC acquired a new position in Avanos Medical during the 4th quarter valued at about $177,000. Vident Advisory LLC acquired a new position in Avanos Medical during the 4th quarter valued at about $585,000. State of Tennessee Department of Treasury boosted its stake in shares of Avanos Medical by 50.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 41,405 shares of the company’s stock valued at $465,000 after purchasing an additional 13,799 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new position in shares of Avanos Medical in the 4th quarter valued at about $201,000. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.